Clinical efficacy and safety of milrinone in the treatment of patients with systemic inflammatory response syndrome and heart failure
10.13699/j.cnki.1001-6821.2015.22.005
- VernacularTitle:米力农治疗全身炎症反应综合征合并急性心力衰竭的临床疗效及安全性评价
- Author:
Zhi XU
1
;
Yu-Qiong FU
;
Feng-Cheng XU
;
Ming-Jun YAN
Author Information
1. 郫县人民医院
- Keywords:
systemic inflammatory response syndrome;
heart failure;
milrinone;
cedilanid;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2015;31(22):2193-2195
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluated the clinical effects and safety of mil-rinone in the treatment of patients with systemic inflammatory response syndrome ( SIRS) and heart failure.Methods Seventy-six cases with SIRS and heart failure were divided into control group ( n =35 ) and experiment group ( n =41 ) .Patients in the control group were given cedilanid 0.2-0.4 mg+5% glucose 20 mL intravenous injection 1-2 times a day for 5 days.Patients in the experiment group were given milri-none 5 -10 mg +5% glucose 250 mL intravenous infusion with 0.4-0.6 μg·kg -1·min-1 1-2 times a day for 5 days.The clinical efficacy, serum brain natriuretic peptide ( BNP ) , heart rate ( HR ) , systolic blood pressure(SBP), diastolic blood pressure(DBP), cardiac output ( CO ) , left ventricular ejection fraction ( LVEF ) as well as the incidence of adverse drug reactions were compared between the two groups.Results After treatment, the clinical efficacy were 92.68%and 94.29% in the experiment and control group respectively without significant difference( P>0.05).After treatment, the serum BNP, HR, DBP and SBP significantly decreased in the two groups with significant difference(P<0.05), and the CO and LVEF significantly increased in the two group(P<0.05).The adverse drug reactions rate were 4.9%and 8.6%in the experiment and control group respectively without significant difference(P>0.05).Conclusion Milrinone was effective and safe in the treatment of patients with in-flammatory response syndrome and heart failure.
